APAC Ulcerative Colitis Market

APAC Ulcerative Colitis Market Size & Growth (2023 to 2028):

The Ulcerative Colitis Market in Asia Pacific is valued at USD 0.92 billion in 2023 and is projected to grow at a CAGR of 7.9%, to reach USD 1.34 billion by 2028 during the forecast period 2023 to 2028. 

The rising prevalence of ulcerative colitis disease, which affects a large number of people, is driving the expansion of the APAC ulcerative colitis market. One of the major factors regulating the industry is the advent of biosimilar. Biosimilars should be less expensive than biologics, making them more affordable in this country. One of the factors driving the emergence of new biosimilar is the projected patent expiration of some drugs.

The industry is estimated to exhibit as key businesses become more involved in product development connected to the field. Pfizer Inc., for instance, started a phase III clinical trial in June 2022 to evaluate tofacitinib's effectiveness, safety, and pharmacokinetics (PK) in pediatric patients with moderately to severely active Ulcerative Colitis. In 2028, the experiment is expected to be completed. Takeda Pharmaceutical Company Limited began a phase III research trial in Japan in June 2022 to evaluate the efficacy and safety of intravenous (IV) Vedolizumab in Japanese patients with moderate to severe Ulcerative Colitis.

The number of patients diagnosed with inflammatory bowel disease (IBD) over the age of 65 is increasing. This is attributable to the increased prevalence of inflammatory bowel disease and an ageing population. In geriatric and adult individuals with ulcerative colitis, the symptoms and behavior are comparable. The aged, on the other hand, are more vulnerable due to comorbidities, higher infection risk, and disease-related consequences. Furthermore, significant R&D and investment by key players in the production of new medicines for UC therapy, as well as an increase in government and non-government organizations funding biologics research, are fueling market expansion.

The market is restrained by the expiration of medication patents and strict government restrictions governing biosimilar approval. Over the forecast period, factors such as high levels of unmet clinical need in ulcerative colitis (UC) and medication side effects are likely to stymie market expansion.

This research report on the APAC Ulcerative Colitis Market has been segmented and sub-segmented into the following categories:

By Product:

• Monoclonal Antibodies
• Biosimilars
• Pharmaceuticals

By Type:

• Proctosigmoiditis
• Ulcerative Proctitis
• Pancolitis
• Left Sided Colitis

By Route Of Administration:

• Oral
• Injectable

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Due to the presence of major companies and the rising prevalence of Ulcerative Colitis in the area, as well as continued investment for the development of new therapies for the treatment of the ailment, Asia Pacific is likely to lead the ulcerative colitis market.

India’s high frequency of ulcerative colitis disease fuels the ulcerative colitis market's growth. Furthermore, the country's market growth is being fueled by improvements in infrastructure and the rise of the drug development sector. Furthermore, a strong government initiative aimed at improving healthcare facilities via favorable insurance plans.

China, India, and Japan are the three largest contributors to the market. The expanding healthcare infrastructure in these countries is mostly related to significant government spending in the healthcare sector. Rapid urbanization and changing eating habits are also expected to boost the industry in the Asia pacific region significantly. Because of its established healthcare industry and growing awareness of IBD, Japan has a significant portion of the Asia-Pacific Ulcerative Colitis market.

The Top companies leading in the APAC Ulcerative Colitis Market profiled in the report are Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche and Shire Pharmaceuticals.